Not exact matches
In a study recently published in the journal Nature Biotechnology, HSCI researchers at Harvard University and Massachusetts General Hospital (MGH), in collaboration with Boston Children's Hospital and Dana Farber Cancer Institute, have developed a non-toxic
transplantation procedure using antibodies to specifically target blood stem
cells in mice, an
approach they hope will make blood stem
cell transplants for these patients far less toxic.
Dr. Cooper joined MDACC in 2006 as section chief of
cell therapy at the Children's Cancer Hospital, where he cared for children undergoing bone marrow
transplantation and led scientific efforts to develop new treatment
approaches that pair genetic engineering with immunotherapies.
«Protection for the gut barrier: New
approach may prevent graft - versus - host disease: Activating signal paths could protect patients from dangerous immune reactions after stem
cell transplantations.»
As for treatments, the paper states, «Stem
cell transplantation may prove to be a viable
approach to treat diseases such as suPAR - associated kidney disease.»
However, coreceptor - specific ZFNs represent a novel therapeutic
approach to recapitulate this success via autologous
transplantation of gene - modified hematopoietic stem
cells and mature CD4 + T
cells.
Treatment
approaches may include chemotherapy, radiation therapy, and rarely, stem
cell transplantation.
Our group is specifically working on improvement of islet isolation and
transplantation protocols in clinical practice and the development of novel therapeutic options in the field of beta
cell replacement with a clear translational «bench to bedside»
approach by linking experimental research with preclinical and clinical work:
Led by our faculty team of 25 physicians and scientists, our patients benefit from a team
approach that includes our colleagues in radiology, surgery, radiation therapy, hematopathology, and stem
cell transplantation, as well as clinical pharmacists, research and clinical nurses, social workers, and dietitians.
Dominic Eberle (Ader, TUD)-- «
Cell transplantation and gene therapy
approaches for the treatment of retinal degenerative disorders» (2012)
He noted that while no technique has emerged as a proven clinical
approach, the use of human rather than rodent
cells as demonstrated by Pollok et al. is an important step in advancing the science behind liver
cell transplantation.
This
approach has been reported to enhance the outcome of
cell transplantation, due to increased
cell retention in the site of
transplantation.
In terms of which
approaches people are taking which might bear fruit clinically most quickly; could you compare the
transplantation encapsulation strategies with a stem
cell based immune response - centered
approach?
«Besides the applications this
cell engineering and
transplantation approach may find in regenerative medicine, our findings support the broader concept that enhancing the function of interneurons can counteract key aspects of Alzheimer's disease,» said Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease.
Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem
cell transplantation based on the patient's risk for relapse.2 This
approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.